TAM
AMAM

Tocqueville Asset Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Tocqueville Asset Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,500
Closed -$112K – 555
2023
Q1 		$112K Buy
+12,500
New +$62.8K ﹤0.01% 515

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Tocqueville Asset Management's AMAM Position: Q2 2023 in Review

Tocqueville Asset Management sold out of Ambrx Biopharma Inc (AMAM) in Q2 2023, closing a stake of 12,500 shares — an estimated $112K sold.

Tocqueville Asset Management first reported a position in AMAM in Q1 2023 and held it in 1 quarter. The position peaked at $112K in Q1 2023. 42 funds tracked by Wall St. Rank hold AMAM as of Q2 2023.

  • Tocqueville Asset Management reported no remaining Ambrx Biopharma Inc position as of Q2 2023 after selling out during the quarter.
  • Tocqueville Asset Management sold 12,500 Ambrx Biopharma Inc shares in Q2 2023, an estimated $112K.
  • Tocqueville Asset Management first reported a position in Ambrx Biopharma Inc in Q1 2023 and held it in 1 quarter.
  • Tocqueville Asset Management's Ambrx Biopharma Inc position peaked at $112K in Q1 2023.
  • 42 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q2 2023.

Based on Tocqueville Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.